Sökning: WFRF:(Dukat Andre) > (2023) > IGFBP-7 and Outcome...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 04861naa a2200733 4500 | |
001 | oai:DiVA.org:uu-512637 | |
003 | SwePub | |
008 | 240522s2023 | |||||||||||000 ||eng| | |
009 | oai:gup.ub.gu.se/323085 | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-5126372 URI |
024 | 7 | a https://doi.org/10.1016/j.jchf.2022.09.0042 DOI |
024 | 7 | a https://gup.ub.gu.se/publication/3230852 URI |
040 | a (SwePub)uud (SwePub)gu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Adamson, Carly4 aut |
245 | 1 0 | a IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction :b Findings From DAPA-HF. |
264 | 1 | b Elsevier BV,c 2023 |
338 | a print2 rdacarrier | |
520 | a BACKGROUND: Insulin-like growth factor-binding protein-7 (IGFBP-7) has been proposed as a potential prognostic biomarker in heart failure (HF), but the association between elevation in IGFBP-7 and HF outcomes in ambulant patients with heart failure with reduced ejection fraction (HFrEF) is unknown. OBJECTIVES: The authors addressed this question in a post hoc analysis of the DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure) trial. METHODS: The primary outcome was a composite of cardiovascular death or a worsening HF event. The risk of adverse outcome was compared across tertiles of IGFBP-7 concentration by means of Cox proportional hazard models adjusted for N-terminal pro-B- type natriuretic peptide (NT-proBNP) and high-sensitivity troponin T (hsTnT). The efficacy of randomized treatment across IGFBP-7 tertiles was assessed. Change in IGFBP-7 at 12 months was compared with the use of geometric means. RESULTS: A total of 3,158 patients had IGFBP-7 measured at baseline, and 2,493 had a repeated measure at 12 months. Patients in the highest tertile of IGFBP-7 had evidence of more advanced HFrEF. The adjusted HR for the primary endpoint in tertile 3, compared with tertile 1, was 1.48 (95% CI: 1.17-1.88). There was no modification of the benefit of dapagliflozin by baseline IGFBP-7 (P interaction = 0.34). Dapagliflozin did not change IGFBP-7 levels over 1 year (P = 0.34). CONCLUSIONS: Higher IGFBP-7 in patients with HFrEF was associated with worse clinical profile and an increased risk of adverse clinical outcomes. IGFBP-7 provided prognostic information incremental to clinical variables, NT-proBNP, and hsTnT. The benefit of dapagliflozin was not modulated by IGFBP-7 level. (Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure [DAPA-HF]; NCT03036124). | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kardiologi0 (SwePub)302062 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cardiac and Cardiovascular Systems0 (SwePub)302062 hsv//eng |
653 | a *Heart Failure/drug therapy | |
653 | a *Ventricular Dysfunction | |
653 | a Left | |
653 | a biomarker | |
653 | a dapagliflozin | |
653 | a heart failure | |
653 | a Humans | |
653 | a Insulin-Like Growth Factor Binding Proteins | |
653 | a insulin-like growth factor-binding protein-7 | |
653 | a Proportional Hazards Models | |
653 | a SGLT2 inhibitor | |
653 | a Stroke Volume | |
700 | 1 | a Welsh, Paul4 aut |
700 | 1 | a Docherty, Kieran F.4 aut |
700 | 1 | a de Boer, Rudolf A.4 aut |
700 | 1 | a Diez, Mirta4 aut |
700 | 1 | a Drozdz, Jaroslaw4 aut |
700 | 1 | a Dukat, Andre4 aut |
700 | 1 | a Inzucchi, Silvio E.4 aut |
700 | 1 | a Kober, Lars4 aut |
700 | 1 | a Kosiborod, Mikhail N.4 aut |
700 | 1 | a Ljungman, Charlotta,d 1977u Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine4 aut0 (Swepub:gu)xljcha |
700 | 1 | a Martinez, Felipe A.4 aut |
700 | 1 | a Ponikowski, Piotr4 aut |
700 | 1 | a Sabatine, Marc S.4 aut |
700 | 1 | a Morrow, David A.4 aut |
700 | 1 | a Lindholm, Daniel4 aut |
700 | 1 | a Hammarstedt, Ann4 aut |
700 | 1 | a Boulton, David W.4 aut |
700 | 1 | a Greasley, Peter J.4 aut |
700 | 1 | a Langkilde, Anna Maria4 aut |
700 | 1 | a Solomon, Scott D.4 aut |
700 | 1 | a Sattar, Naveed4 aut |
700 | 1 | a McMurray, John J. V.4 aut |
700 | 1 | a Jhund, Pardeep S.4 aut |
710 | 2 | a Göteborgs universitetb Institutionen för medicin, avdelningen för molekylär och klinisk medicin4 org |
773 | 0 | t JACC. Heart failured : Elsevier BVg 11:3, s. 291-304q 11:3<291-304x 2213-1779x 2213-1787 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-512637 |
856 | 4 8 | u https://doi.org/10.1016/j.jchf.2022.09.004 |
856 | 4 8 | u https://gup.ub.gu.se/publication/323085 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.